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Abstract Neither effective salvage regimens nor the
outcome and response to retherapy with rituximab contain-
ing chemotherapy have been defined for rituximab pre-
treated patients with relapsing aggressive lymphoma. We
report here a single-centre retrospective outcome analysis of
second-line immunochemotherapy with rituximab. In 28
patients with relapsed or refractory diffuse large B cell
lymphomas, first-line immunochemotherapy had induced
objective responses in 18 patients. Nine of 28 patients
responded to rituximab containing salvage therapy, leading
to a median overall survival of 243 days after start of
second immunochemotherapy. Long-term disease free
survivors (1,260 and 949 days) were restricted to the group
of twelve patients that had received allogeneic stem cell
transplantation as consolidation therapy. In 21 patients with
relapsed mantle cell lymphomas (MCL), 19 patients had
reached remissions with first-line therapy. Of those, 16
patients experienced responses to salvage therapy with a
median overall survival of 226 days. Noteworthy, none of
patients with initial non-responding disease reached a
remission with second immunochemotherapy. Seven
patients with MCL stayed free from progression after
high-dose therapy with autologous or allogeneic stem cell
transplantation in two and five cases, respectively. In
summary, responses to repeated immunotherapy with
rituximab were observed in approximately one third and
two thirds of initially responding patients with aggressive B
cell lymphoma and mantle cell lymphoma, respectively, but
not in primarily refractory disease. Lasting remissions were




The addition of the monoclonal anti-CD20 antibody
rituximab to standard chemotherapy regimens significantly
improved treatment results for patients with aggressive B
cell non-Hodgkin lymphoma, increasing response rates, as
well as progression free and overall survival of patients in
all prognostic subgroups [1–4]. Approximately one third of
patients with diffuse large B cell lymphoma (DLBCL),
however, experience relapse of disease [3–5], and treatment
of such patients remains a major problem. For patients who
had not received initial immunochemotherapy (ICT) with
rituximab-containing regimens, several studies showed that
the addition of rituximab increased the response rates to
salvage protocols such as dexamethasone, high-dose cytar-
abine, and cisplatin (DHAP) [6], ifosfamide, carboplatin,
and etoposide (ICE) [7], or gemcitabine/oxaliplatin [8],
allowing to proceed to high-dose consolidation followed by
stem cell transplantation. The PARMA trial established
high-dose chemotherapy with autologous stem cell trans-
plantation as the standard approach for patients with
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Martin et al. reported a series of 163 patients with
aggressive B cell lymphoma confirming the role of
intensified ICT in the relapse situation, however, also
documenting a significantly worse outcome for those 94
patients, who had relapsed following initial rituximab-
containing regimens [10]. Overall, data on outcome after
repeated rituximab therapy for patients in relapse after
initial ICT are still scarce, and the optimal strategy to
achieve consolidation of second remission is currently
unknown (reviewed in [11]). Similarly in mantle cell
lymphoma (MCL), several studies have documented the
value of ICT with rituximab to improve response rates,
progression free, and overall survival [11]. Approaches
combining rituximab with high-dose chemotherapy regi-
mens including methotrexate and cytarabine with and
without stem cell support led to further improvements of
treatment results, still leaving, however, a significant
proportion of patients to relapse [12–14]. Again, patients
were found to experience significant benefit from the
addition of rituximab to salvage protocols [15], and data
for patients in the situation of relapsed disease following
initial rituximab exposure are scarce. We report here a
retrospective analysis from a lymphoma referral centre,
analysing patients with aggressive lymphomas failing from
first-line immunochemotherapy with R-CHOP-like regi-
mens (rituximab, cyclophosphamide, adriamycin, vincris-
tine, and prednisone). This analysis was conducted to
expand the data on the response rate to second-line ICT




On the basis of ICD-10 coding C83 and C85.1, we
identified 51 lymphoma patients treated between December
2002 and May 2008 at the University Medicine Goettingen,
Germany. Included were subjects with histopathologically
confirmed diagnosis of DLBCL and MCL at age >18 years
that received salvage/retherapy with at least one cycle of
rituximab due to primarily refractory or relapsed lymphoma
after first-line immunochemotherapy with rituximab.
Patients with primary central nervous system involvement,
CD20 negative B cell lymphomas, maintenance therapy
with Rituximab for MCL patients within trials, and absence
of progression or refractory disease were ineligible. Patients
were included independent from a participation in clinical
trials. This retrospective analysis of treatment was submit-
ted to the ethics committee of the University Medicine of
Goettingen, Germany, and no objections were raised.
Design of analysis/response assessment
Data acquisition comprised information concerning time of
diagnosis, age at diagnosis, gender, stage of disease
according to the Ann Arbor classification, B symptoms,
Eastern Cooperative Oncology Group performance status,
bone marrow involvement, lactate dehydrogenase summar-
ised in the International Payment Instruction (IPI), applied
first immunochemotherapy, and response to first-line
therapy (complete remission/partial remission (CR/PR) vs
stable disease/progressive disease (SD/PD)), number of
given rituximab cycles in first-line therapy, time to
progression, and relapse after first ICT, respectively. Further
information included high-dose therapy including autolo-
gous and allogeneic stem cell transplantation (matched and
mismatched related vs unrelated donors), date of last to
follow up, status of disease at last follow up, as well as
death. Progression free survival was defined as the interval
between start of initial or second immunochemotherapy and
death or lymphoma progression, whichever occurred first.
Response was defined as CR/PR in imaging meaning a
reduction of tumour load more than 50% in volume after
therapy regardless of the duration, non-response, therefore,
was progressive disease/no change or reduction of tumour
load less than 50%. Patients who died without documen-
tation of progression were considered to have had tumour
progression on the date of death, unless documented
evidence indicated that no progression occurred. Data
acquisition was based on recorded patient files and survival
information acquired from public registration office. Un-
available data were censored.
Statistical analysis
Progression-free survival was calculated from the date of
diagnosis to documented disease progression; observations
were censored on the date the patient was last known to be
alive, or for patients dying as a result of causes unrelated to
lymphoma or treatment at the date of death. Overall
survival was calculated from the date of diagnosis or the
start of second immunochemotherapy until death as a result
of any cause or date last known alive. The times to event
distributions were estimated using the Kaplan–Meier
method. All statistics were calculated using Statistica
8 software.
Results
Response to second-line immunotherapy
Fifty-one patients with prior rituximab immunochemother-
apy were eligible for this retrospective analysis, 28 with
284 Ann Hematol (2010) 89:283–289relapsing or progressive DLBCL, and 23 patients with
relapse of MCL (Table 1) with a median follow up of
497 days for DLBCL and 1,051 days for MCL after initial
diagnosis. The median time to treatment failure after first
ICT with R-CHOP-like regimens was 225 days (range 71–
963) in DLBCL and 374 days (range 60–1,470) in MCL
(Table 1a).
The second ICT patients received rituximab at a mean
number of 2.1 courses in DLBCL (range 1–4) and 2.6
courses (range 1–6) in MCL with 375 mg/m
2 each, together
with chemotherapy consisting mainly of R-DHAP and R-
ICE (Table 1a). Six out of 28 patients with DLBCL and one
with MCL received dexamethasone and carmustine, etopo-
side, cytarabine, and melphalan (DexaBEAM), one patient
with DLBCL, and four patients with MCL received
rituximab and bendamustine. A response to second ICT
with CR/PR was seen in 9 of 28 (32%) patients with
DLBCL and in 16 of 23 (70%) with MCL.
Comparing response to immunotherapy in first- and
second-line therapy, we found that in 18 of 28 (64.3%)
patients with DLBCL the disease had responded to first-line
therapy. Of the responding patients, the disease responded
in 9 of 18 (50%) for a second time, whereas, those patients
that were progressive under R-CHOP-like regimens did not
reach remissions with second-line ICT (Fig. 1). In the
patients with MCL, response to first-line immunochemo-
therapy had been achieved in 21 of 23 (91.3%) patients.
There were consecutive second-line immunotherapy-
induced remissions in 16 of 21 (76.2%) cases. Again,
second-line immunotherapy did not lead to remissions in
those two cases, in which responses to first-line therapy
could not be achieved (Fig. 1). Thus, in patients with
DLBCL and mantle cell lymphoma refractory to primary
rituximab/CHOP-based ICT, rituximab containing ICT
regimens applying DHAP or ICE were ineffective.
Treatment outcome after second-line immunotherapy
in patients with DLBCL
In 19 of 28 patients with relapsed or refractory DLBCL,
salvage ICT was ineffective, and of the remaining nine
patients with responding disease, seven patients experi-
enced second relapse. The median time to treatment failure
from second immunochemotherapy was 74 days (range 13–
415 days, Fig. 2a). Ineffective salvage therapy or secondary
relapses lead to further salvage strategies, mainly consisting
of chemotherapy according to the B acute lymphoblastic
leukaemia protocol and high-dose regimens or palliative
chemotherapy. The median survival since start of second
ICT amounted to 214 days (range 19–1,260 days) in the
group of non-responders and an overall survival for all
patients with DLBCL to 243 days with ten patients alive at
last follow up (Fig. 2b).
Thirteen patients did not proceed to high-dose chemo-
therapy with stem cell transplantation either due to
comorbidity or progressive disease. Only one patient not
receiving transplantation survived beyond one year despite
further treatment in palliative intention in most patients.
Consecutively, fifteen patients received high-dose che-
motherapy followed by autologous transplantation in nine
patients and soley allogeneic transplantation in six patients.
After autologous stem cell transplantation, one patient was
in complete remission, one patient experienced progressive
disease and did not receive further intensified therapy, one
received consolidating allogeneic stem cell transplantation
in partial remission, and five patients with persistent or
progressive disease received an allogeneic transplantation
after further salvage therapy. Of the twelve patients
receiving allogeneic stem cell transplantation, four patients
experienced progressive disease, two patients died due to
treatment related mortality after allogeneic stem cell
transplantation with status of disease not assessed, and,
further, four patients died due to infectious complications
without evidence of disease. Two patients are alive and
without disease at day 1,260 and 949 after start of second
ICT. Thus, the prognosis of patients with relapse of
DLBCL after initial immunotherapy is dismal, with only
rare cases of disease control by secondary immunochemo-
therapy and subsequent high-dose therapy.
Treatment outcome after second-line immunotherapy
in patients with MCL
In our cohort of 23 patients with relapsed mantle cell
lymphoma, the median time to treatment failure from first-
line immunochemotherapy was considerably longer than in
DLBCL patients, i.e., 374 days since diagnosis (range 60–
1,470). Still, a relapse later than 4 years after diagnosis was
recorded only in one patient of this cohort.
Rituximab-containing salvage therapies succeeded in
second remissions for sixteen patients. Five patients did
not respond to second immunochemotherapy, and in seven
patients second remissions were not durable leading to a
median time to treatment failure of 270 days (Fig. 2c).
Therefore, further salvage therapies and consolidating high-
dose therapy followed by either autologous or allogeneic
stem cell transplantations in eight and five patients were
applied. Six patients after autologous transplantations and
all five patients after allogeneic transplantations experi-
enced stable complete remissions. Following allogeneic
transplantation, however, two patients succumbed to infec-
tious complications at day 270 and 419 post-second ICT.
Overall, sixteen patients with relapsed MCL were alive at a
median interval of 336 days after second ICT (range 86–
1,609, mean 591 days, Fig. 2c and d). Thus, second
immunochemotherapy with rituximab was beneficial for
Ann Hematol (2010) 89:283–289 285Table 1 Patients’ characteristics
a DLBCL (number of patients) Percent MCL (number of patients) Percent
Number of patients 28 23
Male/female 14/14 17/6
Median age in years (range) 51 (19–74) 57 (37–76)
N>60 years 8 29 11 48
Stage
1,2 5 18 2 9
3,4 23 82 21 91
IPI≥22 1 7 5 1 3 5 7
Bulky Disease≥7.5 cm 12 43 3 13
First line ICT
R-CHO(E)P 14/21 26 93 22 96
R-MegaCHOEP 1 4
Other 1* 4 1∆ 4
Mean no. rituximab applications (range) 6,21 (1–10) 6,04 (2–8)
radiotherapy 6 21 1 4
Response to first ICT
CR/PR 18 64 21 92
SD/PD 10 36 2 8
b
Median TTF first ICT in days (range) 225 (71–963) 374 (60–1470)
Status pre-second ICT
Early relapse 16 57 14 61
Late relapse (>1 year) 2 7 7 30
Primary refractory 10 36 2 9
Second ICT*
R-DHAP 14 50 6 26
R-ICE 8 29 5 22




Mean number R-applications 2,1 (1–4) 2,6 (1–6)
Second ICT response
CR/PR 9 32 16 70
SD/PD 19 68 7 30
Response second ICT after
a) CR/PR post-first ICT 9/18 50 16/21 76
b) SD/PD post-first ICT 0/10 0 0/2 0
Further therapy
Autologous SCT 9 32 8 35
Autologous/allogeneic SCT 6 21 0 0
Allogeneic SCT 12 43 5 22
Remission allogeneic SCT
CR/PR 6 21 5 22
SD/PD 4 14 0 0
not applicable 2 7 0 0
Listed are the characteristics of patients of a primary and b secondary immunochemotherapy with relapsing DLBCL and MCL
*One cycle rituximab, ifosfamide, etoposide, vincristine plus three cycles of cyclophosphamide, idarubicine, vincristine, DexaBEAM, and autologous SCT
∆Mitoxantrone, chlorambucil, and prednisolone
a1x R-cyclophosphamide, doxorubicin, vincristine, prednisone, 1x R-etoposide, cytarabine, cisplatin and prednisolone; 1x R-dexamethasone, vincristine, high-dose
methotrexate, ifosfamide, cytarabine, etoposide (B-ALL protocol); and 1x R-dexamethasone, gemcitabine and oxaliplatin);
b Ibritumomab tiuxetan
286 Ann Hematol (2010) 89:283–289most patients with relapsed MCL, particularly, if consoli-
dation with high-dose therapy and stem cell transplantation
was provided.
Discussion
A decade after its introduction [16, 17], the monoclonal
anti-CD20 antibody rituximab represents the standard of
care in first-line therapy for patients with aggressive CD20-
positive B cell lymphoma leading to increase in cure and
reducing the risk of relapses. For patients being refractory
to or relapse after initial ICT, the optimal salvage regimens
remain to be defined.
In the present analysis, the efficacy of repeated immuno-
therapy and the long-term outcome were analysed in a cohort
of patients after prior exposure to rituximab. We found an
overall low response rate of 32% (9 of 28 patients) to
rituximab containing salvage therapy in DLBCL, well in
accordance with the findings in comparable cohorts of
patients [18]. Similarly, in the ongoing European phase III
trial comparing the response rates to R-ICE and R-DHAP
salvage therapy followed by high-dose therapy with
autologous stem cell transplantation (CORAL trial), prior
exposure to rituximab was associated with a significant loss
in event-free survival after 24 months, i.e., 66% without
rituximab pre-treatment vs 34% [19]. Noteworthy, none of
our 12 patients with initially refractory disease reached a
remission with second ICT. Thus, therapeutic approaches
comprising immunochemotherapy and autologous stem cell
transplantation seem insufficient to induce long-lasting
remission for the majority of patients with refractory
DLBCL. Also for patients with relapses of mantle cell
lymphoma after front-line induction ICT, salvage therapy
with rituximab therapy yielded lower response rates when
compared to the situation in rituximab naive patients [20].
The response rate of 69% (16 of 23 patients) in patients
with MCL, however, compares favourably to the dismal
situation in DLBCL. For patients achieving a second
remission, high-dose therapy followed by stem cell trans-
plantation, particularly from an allogeneic source, resulted
in prolonged intervals of progression-free survival intervals.
Fig. 1 Response to second immunochemotherapy depending on the
response to first-line immunochemotherapy with rituximab. Patients
were classified into responders to first ICT or non-responders, defined
as achieving at least partial remission (PR) versus stable disease (SD)
or progressive disease (PD). The proportion diseases responding to
first-line ICT is given on the x-axis. Grey bars indicate responsive
disease to second ICT, whereas, non-response is depicted in black
bars, with absolute numbers of patients displayed within the bars
Fig. 2 Kaplan–Meier estimates
of progression-free survival and
overall survival in patients
with DLBCL and MCL after
second immunochemotherapy.
Time to progression (a, c)
and overall survival (b, d) in
days after second-line
immunochemotherapy are
displayed for patients with
relapsed DLBCL (a, b) and
MCL (c, d). The asterisk (∗)
indicates patients that
received allogeneic stem cell
transplantation
Ann Hematol (2010) 89:283–289 287The mechanisms of resistance to rituximab in the relapse
situation are yet not well understood, but may result from
loss of CD20-antigen expression [21–23], the activation of
Bc e l ls u r v i v a lp a t h w a y s[ 24], an increased expression of the
complement inhibitors CD55 and CD59 [25, 26], or from
impaired functions of the cellular mediators of antibody
dependent cellular cytotoxicity [27–30].
Allogeneic stem cell transplantation was the only option to
induce long-lasting remissions in our cohort of patients with
relapsed aggressive lymphomas, implicating an immunologic
surveillance as the important determinant in tumour
eradication. In the patients with aggressive lymphomas,
remissions were induced in six out of 12 heavily pre-
treated patients, a result also achieved for patients for all
five patients with MCL. Due to its inherent toxicity, as well as
limitations in donor availability, however, allogeneic stem
cell transplantation may not represent a realistic option to
all patients in second remission, documenting an urgent
need for novel agents in the situation of relapsed aggressive
lymphoma.
In summary, responses to second immunotherapy with
rituximab could be achieved for one third of patients with
DLBCL and two thirds of patients with MCL pre-treated
with rituximab. The situation of patients with primarily
refractory disease appears dismal. High-dose chemotherapy
followed by stem cell transplantation, particularly from an
allogeneic donor, was the only option of consolidating
treatment sufficient to secure durable remissions.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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